Sacubitril/Valsartan Improves Cardiac Function and Decreases Myocardial Fibrosis Via Downregulation of Exosomal miR-181a in a Rodent Chronic Myocardial Infarction Model.

Evgeniya Vaskova,Gentaro Ikeda,Yuko Tada,Christine Wahlquist,Marc Mercola,Phillip C. Yang

DOI: https://doi.org/10.1161/JAHA.119.015640

IF: 6.106

2020-06-17

Journal of the American Heart Association

Abstract:Background Exosomes are small extracellular vesicles that function as intercellular messengers and effectors. Exosomal cargo contains regulatory small molecules, including miRNAs, mRNAs, lncRNAs, and small peptides that can be modulated by different pathological stimuli to the cells. One of the main mechanisms of action of drug therapy may be the altered production and/or content of the exosomes. Methods and Results We studied the effects on exosome production and content by neprilysin inhibitor/angiotensin receptor blockers, sacubitril/valsartan and valsartan alone, using human‐induced pluripotent stem cell‐derived cardiomyocytes under normoxic and hypoxic injury model in vitro , and assessed for physiologic correlation using an ischemic myocardial injury rodent model in vivo. We demonstrated that the treatment with sacubitril/valsartan and valsartan alone resulted in the increased production of exosomes by induced pluripotent stem cell‐derived cardiomyocytes in vitro in both conditions as well as in the rat plasma in vivo. Next‐generation sequencing of these exosomes exhibited downregulation of the expression of rno‐miR‐181a in the sacubitril/valsartan treatment group. In vivo studies employing chronic rodent myocardial injury model demonstrated that miR‐181a antagomir has a beneficial effect on cardiac function. Subsequently, immunohistochemical and molecular studies suggested that the downregulation of miR‐181a resulted in the attenuation of myocardial fibrosis and hypertrophy, restoring the injured rodent heart after myocardial infarction. Conclusions We demonstrate that an additional mechanism of action of the pleiotropic effects of sacubitril/valsartan may be mediated by the modulation of the miRNA expression level in the exosome payload. Nonstandard Abbreviations and Acronyms DEMRI delayed gadolinium enhancement MRI DMSO dimethyl sulfoxide HF heart failure iCMs induced pluripotent stem cell‐derived cardiomyocytes LAD left anterior descending LV left ventricular MEMRI manganese‐enhanced MRI MI myocardial infarction MRI magnetic resonance imaging NC negative control Clinical Perspective What Is New? A novel mechanism of action of the pleiotropic effects of sacubitril/valsartan is mediated by the increased production of exosomes and the modulation of their molecular payload. Sacubitril/valsartan treatment resulted in the downregulation of miR‐181a expression in the payload of circulating exosomes in a rodent model of chronic myocardial infarction. The downregulation of miR‐181a resulted in the attenuation of myocardial fibrosis and pathological hypertrophy, restoring the rodent chronic heart failure model. What Are the Clinical Implications? The pharmacologic effects of sacubitril/valsartan in modulating exosome production and molecular payload describe a novel mechanism of action of the physiologic effects and provide a novel platform for pharmacogenomics. Heart failure (HF) is the leading cause of hospital admission in the United States with an increasing mortality rate worldwide. 1 , 2 , 3 The renin‐angiotensin‐aldosterone system is one of the key regulators of cardiovascular homeostasis that exerts its action through the angiotensin II–aldosterone axis. Abnormal cardiac function in HF activates the renin‐angiotensin‐aldosterone system and the sympathetic nervous system. The other counterregulatory pathway activated in HF includes the natriuretic peptide system. One of the key components of the natriuretic peptide system is neprilysin, which catalyzes the degradation -Abstract Truncated-

cardiac & cardiovascular systems